NEW YORK, Dec. 19, 2018
NEW YORK, Dec. 19, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allergan plc ("Allergan" or the "Company") (NYSE: AGN) (ISIN: IE00BY9D5467). Investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980.
The investigation concerns whether Allergan and certain of its officers and/or directors have violated the federal securities laws.
On December 18, 2018, France's National Agency for the Safety of Medicines & Health Products ordered the recall of textured breast implants manufactured by Allergan from the European market, stating that the implants "have been linked to a rare form of cancer"—specifically, anaplastic large cell lymphoma. On December 19, 2018, Allergan stated that it would remove its textured breast implants from the European market. Following these announcements, Allergan's stock price fell sharply during intraday trading on December 19, 2018.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby